Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Fc gamma RIIIA / CD16a

Fc gamma RIIIA / CD16a

Brief Information

Name:Low affinity immunoglobulin gamma Fc region receptor III-A
Target Synonym:Fc Fragment Of IgG, Low Affinity IIIa, Receptor (CD16a),CD16a Antigen,IGFR3,FCG3,Fc Fragment Of IgG, Low Affinity IIIa, Receptor For (CD16),Fc Fragment Of IgG, Low Affinity III, Receptor For (CD16),Immunoglobulin G Fc Receptor III,Fc-Gamma Receptor III-2 (CD 16),Neutrophil-Specific Antigen NA,Fc-Gamma Receptor IIIb (CD16),Fc Gamma Receptor III-A,Fc Gamma Receptor IIIa,Fc-Gamma RIIIa,Fc-Gamma RIII,FCGRIII,FcRIIIa,FCR-10,FCRIII,IMD20,CD16,Low affinity immunoglobulin gamma Fc region receptor III-A,
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Phase 2 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
CD16a VHH - 01 PCC Solid Tumor Solid tumor,Hematoma

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

SCCHO-ATP059H-Cell-based assay
 Fc gamma RIIIA / CD16a FACS

Expression analysis of human CD16a on CHO/Human CD16a (158V) Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human CD16a antibody was performed on CHO/Human CD16a (158V) Stable Cell Line with different expression levels: CHO/Human CD16a (158V) Stable Cell Line (Low Expression); CHO/Human CD16a (158V) Stable Cell Line (Medium Expression); CHO/Human CD16a (158V) Stable Cell Line (High Expression).

SCCHO-ATP059L-Cell-based assay
 Fc gamma RIIIA / CD16a FACS

Expression analysis of human CD16a on CHO/Human CD16a (158V) Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human CD16a antibody was performed on CHO/Human CD16a (158V) Stable Cell Line with different expression levels: CHO/Human CD16a (158V) Stable Cell Line (Low Expression); CHO/Human CD16a (158V) Stable Cell Line (Medium Expression); CHO/Human CD16a (158V) Stable Cell Line (High Expression).

CDA-H52H6-SPR
 Fc gamma RIIIA / CD16a SPR

Human CD16a (F176, S197P) Protein, His Tag (Cat. No. CDA-H52H6) captured on CM5 chip via anti-His antibody can bind Rituximab with an affinity constant of 0.414 μM as determined in a SPR assay (Biacore 8K) (QC tested).

CDA-H82E9-SPR
 Fc gamma RIIIA / CD16a SPR

Biotinylated Human CD16a (V176), Avitag,His Tag (SPR & BLI verified) (Cat. No. CDA-H82E9) captured on Biotin CAP- Series S Sensor Chip can bind Rituximab biosimilar (Cat. No. CD0-M36) with an affinity constant of 0.367μM as determined in a SPR assay (Biacore 8K) (QC tested).

Customer Reviews

Synonym Name

FCGR3A,CD16A,FCG3,FCGR3,IGFR3

Background

CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed  natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
OXS-3550 OXS-3550-TriKE; GTB-3550; OXS-3550; OXIS-3550; 161533-TriKE; 161533 TriKE Oxis Biotech, University Of Minnesota Details
FT-596 FT-596 Phase 1 Clinical Fate Therapeutics Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details
AFM-13 AFM-13 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Mycosis Fungoides Details
FT-538 FT-538 Phase 2 Clinical Fate Therapeutics Inc Solid tumours; Leukemia, Myeloid; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute Details
FT-516 FT-516 Phase 1 Clinical University Of Minnesota, Fate Therapeutics Inc Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours; Abdominal Neoplasms; Coronavirus Disease 2019 (COVID-19); Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms Details
FT-576 FT-576 Phase 1 Clinical University Of Minnesota, Fate Therapeutics Inc Bone Marrow Neoplasms; Multiple Myeloma Details
AFM-24 AFM-24 Phase 2 Clinical Affimed Solid tumours Details
SM-3321 SM-3321 Phase 1 Clinical Beijing StarMab BioMed Technology Ltd Leukemia, Myeloid, Acute Details
GMA-161 GMA-161 Phase 1 Clinical Sanofi, Macrogenics Inc Purpura, Thrombocytopenic, Idiopathic Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message